Pharmaceutical companies continue to inch forward when it comes to addressing access to medicine in low- and middle-income countries, finds the 2021 Access to Medicine Index, published Tuesday 26 January, 2021. There are signs of progress in how they are integrating pro-access approaches into governance structures, R&D processes and monitoring efforts. Yet initiatives addressing access to specific products still remain focused on a few countries. Pfizer moves into the top five. GSK retains its number one position, yet only slightly ahead of Novartis.